China NMPA Product Recall - Fully Automated Fluorescence Immunoassay Analyzer

bioMerieux S.A., through its subsidiary bioMerieux Diagnostics Products (Shanghai) Co., Ltd., has initiated a voluntary Class II recall of its fully automated fluorescence immunoassay analyzer. This action was prompted by a critical software deficiency where the product failed to alert users about expiring calibration dates. Consequently, the analyzer could continue to process tests using outdated calibration curves, potentially compromising the accuracy of patient test results. The recall, identified by Index No. JGXX-2019-10768 and published by the National Medical Products Administration (NMPA) on November 18, 2019, addresses a significant concern for diagnostic reliability. The NMPA, responsible for overseeing medical device safety and quality in China, serves as the regulatory authority for this recall. bioMerieux is taking corrective measures to mitigate the risk associated with this software flaw, ensuring that healthcare providers can rely on the precise performance of their diagnostic equipment. Specific details regarding affected models, specifications, and batches are contained within the official "Medical Device Recall Event Report Form." This proactive recall underscores the company's commitment to patient safety and adherence to regulatory standards for medical devices.